Heartflow (HTFL)

The company’s best-known product is HeartFlow FFRCT Analysis, which estimates fractional flow reserve from a standard cardiac CT scan. This helps clinicians evaluate whether a narrowing in a coronary artery is likely to restrict blood flow, potentially reducing the need for invasive diagnostic procedures in selected patients. HeartFlow also offers Roadmap Analysis, which supports visualisation and interpretation of coronary anatomy, and Plaque Analysis, which helps characterise plaque burden and composition.

HeartFlow operates as a commercial-stage software business serving hospitals, imaging centres, cardiologists, and other healthcare providers. Its products sit at the intersection of cardiovascular care, radiology, and AI-enabled clinical decision support. Rather than manufacturing implantable devices or running diagnostic labs, the company focuses on cloud-based analysis and reporting that can be integrated into existing cardiac imaging workflows.

Coronary artery disease remains one of the most common and costly cardiovascular conditions worldwide, creating demand for tools that can improve diagnosis, risk assessment, and treatment planning. HeartFlow’s proposition is distinctive because it seeks to turn non-invasive imaging into a more complete clinical assessment. The company reports its business as a single operating segment and generates most of its revenue in the United States, with additional activity in Europe and other international markets.